<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30347971</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>23</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">2383-7837</ISSN>                <JournalIssue CitedMedium="Print">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>23</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of pathology and translational medicine</Title>                <ISOAbbreviation>J Pathol Transl Med</ISOAbbreviation>            </Journal>            <ArticleTitle>The Prognostic Impact of Synchronous Ipsilateral Multiple Breast Cancer: Survival Outcomes according to the Eighth American Joint Committee on Cancer Staging and Molecular Subtype.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.4132/jptm.2018.10.03</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">In the current American Joint Committee on Cancer staging system of breast cancer, only tumor size determines T-category regardless of whether the tumor is single or multiple. This study evaluated if tumor multiplicity has prognostic value and can be used to subclassify breast cancer.</AbstractText>                <AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">We included 5,758 patients with invasive breast cancer who underwent surgery at Samsung Medical Center, Seoul, Korea, from 1995 to 2012.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Patients were divided into two groups according to multiplicity (single, n=4,744; multiple, n=1,014). Statistically significant differences in lymph node involvement and lymphatic invasion were found between the two groups (p&lt;.001). Patients with multiple masses tended to have luminal A molecular subtype (p&lt;.001). On Kaplan-Meier survival analysis, patients with multiple masses had significantly poorer disease-free survival (DFS) (p=.016). The prognostic significance of multiplicity was seen in patients with anatomic staging group I and prognostic staging group IA (p=.019 and p=.032, respectively). When targeting patients with T1-2 N0 M0, hormone-receptor-positive, and human epidermal growth factor receptor 2 (HER2)‒negative cancer, Kaplan-Meier survival analysis also revealed significantly reduced DFS with multiple cancer (p=.031). The multivariate analysis indicated that multiplicity was independently correlated with worse DFS (hazard ratio, 1.23; 95% confidence interval, 1.03 to 1.47; p=.025). The results of this study indicate that tumor multiplicity is frequently found in luminal A subtype, is associated with frequent lymph node metastasis, and is correlated with worse DFS.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Tumor multiplicity has prognostic value and could be used to subclassify invasive breast cancer at early stages. Adjuvant chemotherapy would be necessary for multiple masses of T1‒2 N0 M0, hormone-receptor-positive, and HER2-negative cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Chu</LastName>                    <ForeName>Jinah</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bae</LastName>                    <ForeName>Hyunsik</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Seo</LastName>                    <ForeName>Youjeong</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cho</LastName>                    <ForeName>Soo Youn</ForeName>                    <Initials>SY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Seok-Hyung</ForeName>                    <Initials>SH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cho</LastName>                    <ForeName>Eun Yoon</ForeName>                    <Initials>EY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>J Pathol Transl Med</MedlineTA>            <NlmUniqueID>101650151</NlmUniqueID>            <ISSNLinking>2383-7837</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">Disease-free survival</Keyword>            <Keyword MajorTopicYN="N">Molecular subtype</Keyword>            <Keyword MajorTopicYN="N">Multiplicity</Keyword>            <Keyword MajorTopicYN="N">Prognosis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30347971</ArticleId>            <ArticleId IdType="pii">jptm.2018.10.03</ArticleId>            <ArticleId IdType="doi">10.4132/jptm.2018.10.03</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>